Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study.
OBJECTIVE
To determine risk factors of infections with piperacillin/tazobactam-resistant Escherichia coli in critical care patients.


METHODS
Prospective, consecutive sample survey study.


METHODS
Surgical intensive care unit (ICU) in a university hospital.


METHODS
A consecutive series of 133 patients from whom culture results were positive for E. coli during their ICU stay.


METHODS
None.


RESULTS
Multivariate logistic regression analysis identified the following significant independent factors associated with the emergence of a piperacillin/tazobactam-resistant Escherichia coli: prior use of amoxicillin (odds ratio, 4.15) and amoxicillin/clavulanate (odds ratio, 3.25).


CONCLUSIONS
Treatment with amoxicillin or amoxicillin/clavulanate is a major risk factor for the detection of piperacillin/tazobactam-resistant E. coli in ICU patients.
Mohammedi
Ismaël
I
Intensive Care Unit, Edouard Herriot Hospital, Claude Bernard University, 69003, Lyon, France. ismael.mohammedi@chu-lyon.fr
Ploin
Dominique
D
Duperret
Serge
S
Chapuis
François
F
Petit
Paul
P
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D005602:France; D006801:Humans; D007362:Intensive Care Units; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D010878:Piperacillin / Q000494:pharmacology*; D011446:Prospective Studies; D012307:Risk Factors; D000078142:Tazobactam
D000900:Anti-Bacterial Agents; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin